BioDlink Biopharm Co Ltd (HK:1875), a CDMO specialising in biologics and bioconjugates (ADCs/XDCs), announced on Monday the first international shipment of its bevacizumab injection biosimilar to Colombia in partnership with Kexing BioPharm.

Bevacizumab is a monoclonal antibody aimed at vascular endothelial growth factor (VEGF) and is widely used in the treatment of various cancers, including metastatic colorectal cancer (mCRC) and metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC).

The injection received marketing approval from Colombia's National Institute for Surveillance of Medicines and Foods (INVIMA) in July 2025.

Following GMP certification in China, Colombia, Brazil, Argentina, Egypt, Indonesia, Pakistan and Thailand, Kexing BioPharm, the global licensee for bevacizumab injection in emerging markets, has initiated regulatory filings in 35 countries in collaboration with BioDlink.

Since BioDlink signed an international commercialisation agreement with Kexing BioPharm in early 2022, the two companies have achieved a complementary and efficient closed-loop 'R&D-manufacturing-access' model, laying the foundation for the future international launch of additional products. BioDlink focuses on ensuring international manufacturing and supply chain robustness, while Kexing BioPharm leverages its global channels to drive localised market access.